-
公开(公告)号：WO2019168524A1
公开(公告)日：2019-09-06
申请号：PCT/US2018/020209
申请日：2018-02-28
Applicant: LEIDOS, INC.
Inventor： GUTIERREZ, Gabriel, M. , KOTRAIAH, Vinayaka , PANNUCCI, James , AYALA, Ramses
IPC: A61K38/10 , A61K38/16 , A61Q5/00 , A61Q19/02 , A61K48/00 , C12N15/00 , A61P31/00 , A61P31/04 , A61P17/02 , A61P35/00 , A61P17/00
Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor programmed death 1 (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
Patent Agency Ranking
公开(公告)号：WO2018053218A1
公开(公告)日：2018-03-22
申请号：PCT/US2017/051697
申请日：2017-09-15
Applicant: LEIDOS, INC.
Inventor： GUTIERREZ, Gabriel M. , VINAYAKA, Kotraiah , PANNUCCI, James , AYALA, Ramses
Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PDL1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
Abstract translation: 本公开提供了对检查点受体“程序性死亡1”具有强亲和力的肽。 （PD-1）。 这些肽阻断PD-1与其配体PDL1的相互作用，因此可以用于各种治疗目的，例如抑制包括癌症在内的过度增殖性病症的进展，治疗感染性疾病，增强对疫苗接种的反应和治疗败血症。
-
公开(公告)号：EP3795167A1
公开(公告)日：2021-03-24
申请号：EP20204314.7
申请日：2017-09-15
Applicant: Leidos, Inc.
Inventor： GUTIERREZ, Gabriel M. , KOTRAIAH, Vinayaka , PANNUCCI, James , AYALA, Ramses
Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号：EP3512536A1
公开(公告)日：2019-07-24
申请号：EP17778394.1
申请日：2017-09-15
Applicant: Leidos, Inc.
Inventor： GUTIERREZ, Gabriel M. , KOTRAIAH, Vinayaka , PANNUCCI, James , AYALA, Ramses
Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号：EP3758732A1
公开(公告)日：2021-01-06
申请号：EP18712047.2
申请日：2018-02-28
Applicant: Leidos, Inc.
Inventor： GUTIERREZ, Gabriel, M. , KOTRAIAH, Vinayaka , PANNUCCI, James , AYALA, Ramses
-
公开(公告)号：EP3512536B1
公开(公告)日：2020-11-04
申请号：EP17778394.1
申请日：2017-09-15
Applicant: Leidos, Inc.
Inventor： GUTIERREZ, Gabriel M. , KOTRAIAH, Vinayaka , PANNUCCI, James , AYALA, Ramses
-
-
-
-
-
Search Results
6
records
(took 0.02 seconds)
